Revenue
2012
2013
RELMADA THERAPEUTICS, INC. (RLMD)
Price—Loading quote
Net income
2019
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2013
2015
2016
2017
2018
2019
2020
Total cash / debt
CashTotal debt
2019
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 · Dec 31 | 2019 · Jun 30 | 2018 | 2017 | 2016 | 2015 | 2013 | 2012 · Dec 31 | 2012 · Aug 31 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — | — | — | $5,129 | — | $7,941 |
| Gross profit | — | — | — | — | — | — | — | — | — | — | — | — | $1,093 | — | $2,142 |
| Research & development | $26.9M | $46.2M | $54.8M | $113.3M | $90.6M | $36.0M | $7.9M | $7.0M | $2.9M | $1.3M | $6.2M | $7.9M | — | — | — |
| Operating expenses | $59.1M | $83.9M | $103.7M | $161.2M | $125.7M | $60.8M | $15.1M | $12.7M | $6.9M | $7.2M | $16.2M | $17.1M | $46,108 | — | $14,194 |
| Operating income | −$59.1M | −$83.9M | −$103.7M | −$161.2M | −$125.7M | −$60.8M | −$15.1M | −$12.7M | −$6.9M | −$7.2M | −$16.2M | −$17.1M | −$45,015 | −$3.2M | −$12,052 |
| Net income | −$57.4M | −$80.0M | −$98.8M | −$157.0M | −$125.8M | −$59.5M | −$15.0M | −$17.3M | −$9.0M | −$6.3M | −$3.0M | −$20.8M | −$45,015 | −$6.9M | −$12,052 |
| Basic EPSper diluted share | -$1.45 | -$2.65 | -$3.28 | -$5.30 | -$7.16 | -$3.81 | -$1.62 | -$2.74 | -$2.86 | -$0.52 | -$0.26 | -$2.09 | $0.00 | -$3.17 | $0.00 |
| Diluted EPSper diluted share | -$1.45 | -$2.65 | -$3.28 | -$5.30 | -$7.16 | -$3.81 | -$1.62 | -$2.74 | -$2.86 | -$0.52 | -$0.26 | -$2.09 | $0.00 | -$3.17 | $0.00 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Dec 15, 2025Form 4 | TRAVERSA SERGIOChief Executive Officer | BuyCommon Stock | 27.5K | $4.12 | $113.3K | 1.30M |
| Dec 15, 2025Form 4 | Shenouda MagedChief Financial Officer | BuyCommon Stock | 11.7K | $4.12 | $48.1K | 800.0K |
| Nov 5, 2025Form 4 | Ence ChuckCAO and COO | BuyCommon Stock | 136.0K | $2.20 | $299.2K | 403.9K |
| Nov 5, 2025Form 4 | TRAVERSA SERGIOChief Executive Officer | BuyCommon Stock | 272.5K | $2.20 | $599.5K | 1.27M |
| Nov 5, 2025Form 4 | Shenouda MagedChief Financial Officer | BuyCommon Stock | 500.0K | $2.20 | $1.10M | 788.3K |